Form 4: Acrivon Therapeutics CFO Holm-Jorgensen Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Rasmus Holm-Jorgensen, CFO of Acrivon Therapeutics, disposed of 368 shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On May 14, 2024, Rasmus Holm-Jorgensen, the Chief Financial Officer of Acrivon Therapeutics, Inc., disposed of 368 shares of common stock.
- The transaction was executed to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The shares were disposed of at a price of $8.36 per share.
- Following the transaction, Holm-Jorgensen directly owns 27,258 shares of Acrivon Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to insider transactions for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This transaction is related to tax obligations, which is a common occurrence when restricted stock units vest.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of transaction: Rasmus Holm-Jorgensen disposed of shares. |
| 05/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.